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Efficacy of 5-day cefpodoxime proxetil for recurrent 
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Objective: To compare the clinical and bacteriologic efficacy of a 5-day course of cefpodoxime proxetil (CPD) with 
that of a 10-day course of penicillin V (PNV) or amoxycillin-clavulanate (AMC) in recurrent pharyngitis in adults. A cost- 
effectiveness study (reported elsewhere) was carried out at the same time. 
Methods: This multicenter, randomized, open label trial involved 580 adult patients consulting general practitioners 
for clinical recurrent pharyngitis (23 episodes within the last 12 months) regardless of the bacterial etiology. Patients 
were treated for 5 days with CPD, 100 m g  twice daily, or for 10 days with PNV, 1 x l o6  IU three times a day, or for 10 days 
with AMC, 500 m g  (amoxycillin) three times a day. Clinical and bacteriologic outcomes were noted at the end of 
treatment, and cases of clinical recurrenc:e were recorded during a 6-month follow-up period. 
Results: At the end of treatment, clinical response was satisfactory in 157 of 170 (92.3%) patients on CPD, 147 of 166 
(88.5%) patients on PNV, and 168 of 177 (94.9%) patients on AMC. Group A P-hemolytic streptococci (GABHS) were 
eradicated in 22 of 23 (95.65%) patients on CPD, 16 of 16 (100%) patients on PNV, and 19 of 20 (95%) patients on AMC. 
The rates of clinical success and GABHS eradication were not significantly different between the groups. Compliance 
(p<O.OOl) and tolerance (p<O.OOI) were significantly better in  the CPD group than in the other two groups. Among the 
389 patients evaluable 6 months after the end of treatment, the recurrence rate of acute pharyngitis (due to  any 
bacterium) was significantly lower in the CPD group (p=O.Ol versus PNV; p<O.Ol versus AMC). A Kaplan-Meier analysis 
(469 patients over 6 months) of the rate of non-recurrence, with comparison by the log-rank test, also showed a 
significant difference in favor of CPD. 
Conclusions: A 5-day treatment of recurrent pharyngitis with CPD was as effective and better tolerated than a 10-day 
treatment with PNV or AMC. The risk of recurrence was lower with CPD. 
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INTRODUCTION 
The diagnosis of acute pharyngitis is generally based on 
clinical signs and symptoms. In most cases, antibiotic 
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treatment is dictated by the risk of suppurative com- 
plications and, above all, by the risk of failing to 
abrogate pharyngitis due to group A P-hemolytic 
streptococci (GABHS). GABHS pharyngitis represents 
11-50% of cases of acute pharyngitis, and the risk of 
acute rheumatic fever (ARF) after GABHS pharyngitis 
is 1 to 3% in the absence of antimicrobial chemotherapy 
In France, clinicians are advised to treat all cases 
of acute pharyngitis, regardless of the age of the patient, 
and without taking a throat swab for identification of 
[I]. 
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group A streptococci [I]. A 3 0-day course of penicillin 
V (PNV) remains the reference treatment of these acute 
episodes. This therapeutic strategy differs fi-om that 
applied in cases of recurrent pharyngitis, where p- 
lactam agents stable to p-lactamases (second- and third- 
generation cephalosporins, anlinopenicillins combined 
with a p-lactamase inhibitor) are the recommended 
treatment. 
In the literature, the yearly frequency of episodes 
is used as a practical definition of recurrent pharyngitis. 
Depending on the author, recurrent episodes (from 
three to five) can be counted over a 2-year or I-year 
period [2-lo]. 
The pathophysiologic mechanisnis and bacterial 
epidemiology of these episodes of recurrent pharyngitis 
remain to be documented. Potentially predisposing 
factors include bacterial colonization of hypertrophic 
tonsils (2,6,10-12) and the copathogenicity hypothesis 
[13]. The latter is based on the presence of large 
numbers of P-lactamase-producing strains in the tonsils 
of patients with recurrent pharyngitis. Among the 
p-lactam agents used to treat episodes of pharyngitis, 
PNV and aminopenicillins are sensitive to many 0- 
lactamases, and this may possibly explain cases of treat- 
ment failure and recurrence. 
Cefpodoxime proxetil (CPD), a cefpodoxime pro- 
drug, is a p-lactam agent and an oral third-generation 
cephalosporin. In France, as far as the treatment of 
pharyngitis is concerned, CPD should be reserved 
for the treatment of recurrent episodes. Several com- 
parative trials of CPD in the treatment of streptococcal 
pharyngitis have shown that this antibiotic is a safe 
and effective alternative for the eradication of group A 
streptococci 114-161. In addition, a 5-day course of 
cefpodoxime in this setting is as effective in clinical and 
bacteriologic t e r m  (eradication of group A strepto- 
cocci) as a 10-day course of PNV [15,17-201, with a 
clear benefit as regards compliance. 
These observations led us to perform a clinical 
study on adult patients with recurrent pharyngitis to 
compare a 5-day course of CPD with a 10-day course 
of PNV or amoxycillin-clavulanate (AMC). The aims 
of this study were: 
1. to compare the clinical efficacy at the end of treat- 
2. to compare the bacteriologic efficacy in the sub- 
3. to compare the clinical efficacy on the recurrence 
ment; 
group of documented GABHS pharyngitis; 
rate during the 6-month follow-up period. 
Results of the cost-effectiveness study conducted 
in parallel have been published elsewhere [21]. 
This French nationwide multicenter study, conducted 
from March 1992 to January 1993, involved 580 
patients recruited by 204 general practitioners. Each 
investigator had to include at least a block of three 
patients, who were randomly assigned to one of the 
three regimens under study. It was thus a prospective, 
comparative, randonlized, open trial with three parallel 
groups. 
Patients 
Inclusion criteria were as follows: ambulatory patients 
over 15 years of age, of either sex, consulting a general 
practitioner for recurrent pharyngitis. The latter was 
defined by the presence of clinical signs and symptoms 
of bacterial pharyngitis origin (temperature 238 O C ,  
throat pain both spontaneously and on swallowing, 
possible headache, erythematous or erythemato- 
exudative tonsils and pharynx, anterior cervical adeno- 
pathy; no coryza, conjunctivitis, cough or laryngitis) 
and by the frequency of episodes (the current episode 
having to be at least the third in the last 12 months). 
Non-inclusion criteria were as follows: age less 
than 15 years; pregnancy or breast-feeding; sinusitis; 
history of allergy to p-lactam agents; cancer, hemato- 
logic disorder or acquired immunodepression; anti- 
biotic treatment in the previous 72 h; treatment with 
allopurinol; recurrent infectious lung, urinary tract 
or gynecologic disease; unlikely compliance with 6 
months of follow-up. 
All the patients (or the parents of patients less than 
18 years old) gave their informed consent to the study 
and the protocol was approved by a medical ethical 
committee. 
Treatment regimens 
The patients were randomized to one of the following 
oral treatment arms: CPD, one tablet (100 mg) twice 
daily for 5 days; PNV, one tablet (1 x lo6 IU; 600 mg) 
three times a day for 10 days; AMC, one tablet (500 mg 
amoxycillin + 125 mg clavulanate) three times a day for 
10 days. The tablets had to be taken with meals in the 
morning and evening (CPD), or morning, midday and 
evening (PNV and AMC). Treatment allocation was 
managed via a central computer system. Concomitant 
administration of antiseptics, analgesics, antipyretics 
and anti-inflammatory drugs (including steroids) was 
authorized. In contrast, other antibiotics, even in the 
form of mouthwashes, were forbidden. 
Clinical follow-up 
At the enrollment visit (DI), after checking ofinclusion 
and non-inclusion criteria, the patients' demographic 
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data and personal histories were recorded, together 
with details of the current episode of pharyngitis. 
General and local signs (temperature, loss of appetite, 
throat pain, headache, color of the pharynx, adeno- 
pathy) were noted, together with the allocated treat- 
ment, other prescribed drugs and sick leave. The 
patient was seen by the same investigator at an end-of- 
treatment visit (D7-D8 in the CPD group; D12-Dl3 
in the PNV and AMC groups) to assess changes in 
local and general signs, together with compliance, 
tolerability and how the patient felt. All the patients 
treated successfully were seen 6 months later. During 
the follow-up period (from D9 or D14 to D180), the 
patient was contacted by telephone every 2 months to 
record any new episodes of pharyngitis or intercurrent 
infections. When recurrences were diagnosed in the 
practitioner’s office, general and local signs were 
recorded, along with any drug prescriptions. 
Bacteriologic follow-up 
O n  Dl , the investigator took two sw,ibs in random 
order, one for diagnosis of group A streptococcal 
infection by means of a rapid agglutination method 
(Abbott Test Pack, Abbott, USA), and the other for 
culture. These two samples allowed an evaluation of the 
sensitivity of the rapid diagnosis test in routine practice, 
even though this test is not available in France at  
the present time. The samples for culture were obtained 
with Culturette swabs (Becton-Diclrinson, USA), 
which were immediately placed in special transport 
medium for respiratory tract pathogens (Stuart Trans- 
port Medium, UNIPATH, UK) and sent by mail the 
same day to a central laboratory (Laboratoire du Centre 
de Diagnostic du GalilCe, Torcy Marne-la-VallCe, 
France). Only those samples received at the laboratory 
within 3 days after sampling were taken into account 
to describe the potential pathogens. Description of 
the potential pathogens was applied to the following 
selection of bacteria yielded by culture: all group A, C 
and G P-heniolytic streptococci (irrespective of their 
quantity); Haemophilus injluenzae and Staphylococcus 
aweus cultured from samples not containing strepto- 
cocci; Enterobacteriaceae and non-fermenting Gram- 
negative bacilli cultured from samples containing none 
of the above pathogens. Strains of the two last groups 
of bacteria were taken into account only when present 
in culture in significant amounts. Culture of a further 
throat swab was performed at the end of treatment 
under the same conditions as at the enrollment visit. 
Assessment of clinical efficacy 
At the end of treatment, clinical efficacy was judged 
satisfactory if the infection was clinically cured or 
improved. Efficacy was judged unsatisfactory if the 
infection had deteriorated or if the patient’s condition 
had not improved. It was unevaluable if the study drug 
had been taken for less than 5 days (or less than 48 h in  
case of failure) or if inclusion/non-inclusion criteria 
were not respected. The time (in days) required for 
the patients to feel better or cured was noted by the 
investigator on a daily record card filled in by the 
patient. 
At the end of the follow-up period, treatment was 
judged successful if no further episode of pharyngitis 
had occurred by D180. Recurrence was defined as the 
onset of a new episode of pharyngitis after the end-of- 
treatment visit. Efficacy was unevaluable in the follow- 
ing cases: no follow-up visit or no contact within 6 
months after the beginning of treatment; unsatisfactory 
or unevaluable clinical efficacy at  the end-of-treatment 
visit; prescription of another antibiotic during the 
follow-up period for an intercurrent infection. 
Evaluation of efficacy by means of Kaplan-Meier plots 
All the patients in whom clinical efficacy was judged 
satisfactory at the end-of-treatment visit were included 
in this analysis. The number of days without recurrence 
was defined as the difference between the first day of 
treatment and either the date of recurrence, the date of 
loss to follow-up without clinical recurrence, or the 
date of the first dose of antibiotics for an inter- 
current infection. Kaplan-Meier survival curves were 
constructed from these data for each treatment group. 
Evaluation of bacteriologic efficacy 
This analysis only took into account group A strepto- 
cocci, the only organism clearly identified as patho- 
genic in pharyngitis. Patients eligible for this analysis 
were those evaluable for clinical efficacy, by protocol, 
at the end of treatment, who had group A streptococci 
cultured from their first sample. Samples received 
within 7 days by the central laboratory (initial sample 
and end-of-treatment sample) were taken into account, 
in order to describe the maximum number of strepto- 
coccal pharyngitis cases. Bacteriologic efficacy at the 
end of treatment was judged satisfactory if group A 
streptococci were eradicated, and otherwise as unsatis- 
factory. 
Evaluation of tolerance 
Tolerance was assessed froin the data collected at  the 
end of treatment on the basis of the number of patients 
who experienced one or more adverse events in each 
treatment group. 
Evaluation of compliance 
Compliance, judged by the number of tablets taken 
(recorded by the investigator), was considered good if 
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at least 80% of the treatment course had been taken 
(eight tablets of CPD or 24 tablets of PNV or AMC). 
Statistical analysis 
The number of subjects necessary to show a difference 
of 10% between CPD and one of the other study drugs 
was 395 per treatment group, assuming a clinical success 
rate of 95% at the end of treatment, with a first-order 
risk of 2.5% and a second-order risk of 2.5% (instead 
of 5%, as there were three treatment groups). 
The relapse rate at 6 months with the reference 
treatment was unknown. The power of comparisons 
involving recurrence rates based on survival curves was 
thus calculated retrospectively, and was 90% for the 
cornparison of CPD with AMC, and 80% for the 
comparison of CPD with PNV 
Comparisons of frequencies were made using the 
chi-squared test or Fisher’s exact test. In cases of an 
overall difference between the three groups, the CPD 
group was compared with each of the other two 
groups. The comparison of changes in qualitative 
parameters was based on the Mantel-Haenszel adjusted 
chi-squared test. Means were compared using one- 
way analysis of variance; in case of a significant overall 
difference, the groups were compared two-by-two 
using Dunnet’s T test. Recurrences after successful 
treatment were analyzed by the Kaplan-Meier method. 
The three treatments were compared by means of 
the log-rank test, and then two-by-two when the 
difference was significant. In addition, a Cox model was 
used to identify variables with independent influence 
on the recurrence rate. The variables entered in the 
model were those recorded at enrollment and found to 
have significant influence in a univariate analysis. 
Description of the population 
Among the 580 patients randomized between March 
1992 and June 1992, five were excluded from the 
analyses (four lost to follow-up, one took no treat- 
ment); 575 patients were thus evaluable for analysis of 
clinical tolerance. The evaluation of clinical efficacy 
at the end of treatment involved 513 patients, as 62 
patients were excluded because of major deviations 
from the protocol. Among these 513 patients, 469 
were evaluable for long-term outcome, while 44 were 
unevaluable; the outcome of treatment had been a 
clinical failure in 41 of them, and three had received 
another antibiotic at the end of treatment, based on the 
results of throat culture. In total, 389 patients were 
included in the assessment of clinical efficacy during 
follow-up, as 124 patients were unevaluable (44 patients 
excluded from the Kaplan-Meier analysis, 70 patients 
who had received an antibiotic for an intercurrent 
infection during the follow-up period, and 10 patients 
whose final visit had not taken place at M6 or M7). 
Among the 575 patients evaluable for tolerance 
(205 men and 370 women; median age 33.7k12.6 
years; mean body weight 64.1 k 13 kg), the demo- 
graphic characteristics, medical history and presenting 
signs and symptoms were comparable in the three 
groups (Table 1). The analysis of the same parameters 
in the population eligible for the analysis of clinical 
efficacy also failed to show significant differences 
between the three groups. 
Clinical efficacy by protocol at the end of treatment 
In the 513 patients evaluable for this analysis, the rate 
of satisfactory clinical responses was not significantly 
different between the three groups (Table 2). Among 
the patients in whom the clinical response was satis- 
factory, the mean time required for a subjective im- 
provement was significantly shorter on CPD (2.5 F 0.8 
days) thanonPNV (3.3k1.3days) andAMC (3.321.3 
days) (global comparison, p<0.001). Similarly, the time 
required for a subjective cure was significantly shorter 
on CPD (4k1.3 days) than on PNV(5.4F1.9 days) and 
Table 1 Clinical and demographic characteristics of patients evaluable for tolerance 
CPD 
iw=188) 
PNV AMC 
(?I = 187) (?I =200) P 
Demographic characteristics 
Age (years, m f SD) 
Weight (kg, m +SD) 
Sex (M/F) 
33.37k12.29 
65.07f13.66 
72/116 
Medical history 
Nuniber of episodes in last 12 months (nifSD) 
Tonsillectomy (yes/no) 16/172 
Date of last pharyngitis (days, m i  SD) 
Timc from clinical onset (days, NI k SD) 
4.2651.22 
70.07k43.89 
2.052331 
34.03f 12.81 33.64F12.75 NS 
63.71 2 12.34 63.63k12.48 NS 
62/ 125 71/129 NS 
4.2521.30 4.21 f1 .18  NS 
20/ 167 261174 NS 
71.58147.26 73.86547.38 NS 
1.89 k2.47 1.90f2.26 NS 
CPD=cefpodoxinie proxetil; PNV=penicillin V; AMC=amoxycillin + clavulanic acid; NS=not significant; m=niean. 
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Table 2 AnalyTiT of clinical efficacy by protocol at the end 
of treatment 
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CPI) PNV AMC 
Clinical re.;ponsr (rr=17iI) (rr=166) (n=177) 
Satisfactory (94) * 157 (92.35) 147 (88.55) 168 (94.92) 
Unsatisfactory (‘X) 13 (7.65) 10 (1 1.45) 9 (5.08) 
CPD=cefpodoxinie proxetil; PNV=prnicillin V; 
AMC=anioxycillin + clavulanic acid; *p=O.O9. 
AMC (5.6 k 2.2 days) (global comparison, p<0.001). 
This difference was also found in the Kaplan-Meier 
plots of subjective amelioration and cure among the 
patients who were evaluable at the end of treatment. 
Clinical efficacy by protocol at the end of follow-up 
The recultc obtxned in the 389 evaluable patients 
(Table 3) show that the rate of non-iecurrence was 
significantly higher in the CPD group than in the PNV 
group (p=0.01) and AMC group (p<0 01). In contract, 
no significant difference was found as regards the mean 
time to recurrence (Table 3).  
Clinical efficacy: Kaplan-Meier plots 
Figure 1 shows the ‘non-recurrence’ curves in the 
three treatment groups. The three curves were globally 
different. Two-by-two comparisons (log-rank test) con- 
firmed the absence of a significant difference between 
the PNV and AMC curves. In contrast, the CPL) curve 
differed significantly from the PNV curve (p=O.Ol)  and 
the AMC curve (p<0.01). 
The influence of treatment on the onset of recur- 
rences was studied by means of a Cox model, which 
confirmed that recurrences during follow-up were 
linked to the study drug, even after adjustment for 
baseline variables (type of treatment, sex, salaried job, 
age in two arbitrary classes (<40 years and 240 years), 
tonsillectoniy, temperature at  inclusion >38 “C, and 
number of episodes of pharyngitis in the previous 12 
months, also divided into two classes relative to the 
Table 3 Clinical efficacy at follow-up (month 6 or nionth 7): comparison of the recurrence rate according to treatment (per 
protocol analysis) 
CPD I’NV AMC 
(If = 130) (11  = 122) (r1=137) I’ 
Success no. (‘2%) 108 (83.08) 
Krcurrerice no. (“A) 22 (16.92) 
Timc to recurrence (days, nieaii f SEM) 84 ? 5 i  1 
85 (69.67) 
37 (30.33) 
81f49  
94 (68 61) <ij 001 
43 (31 30) 
7 8 f 4 1  NS 
CPL>=cefpodoxime yroxetil; PNV=penicilliii V; AMC=amoxycillin + clavulaiiic acid; NS=not significant 
I I I I 
0 30 60 90 120 150 180 
05 ,I 
Days from beginning of treatment 
Figure 1 Kaplan-Meier plots of non-recurrence in patients with satisfactory clinical results at  the end of treatment. 
~ cefpdoxinic proxetil ( ~ ~ 1 5 6 ) ;  . . . . . .  penicillin V (n=147); - - - - arnoxycillin-clavulanate (11=l66). 
4 5 2  Clinical  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  V o l u m e  3 N u m b e r  4,  A u g u s t  1997 
median of episode number (<4 per year and 2 4  per 
The results of the Cox model used to identie 
parameters independently linked to recurrences showed 
that these were significantly less frequent after treat- 
ment with CPD than with PNV and AMC (p<0.002), 
less frequent in patients over 40 (p<O.OOl), and more 
frequent in patients who had had at least four previous 
episodes. 
Year)). 
Pathogens isolated at inclusion 
The rapid diagnostic test for group A streptococci had 
a sensitivity of 73%, a specificity of 91%, a positive 
predictive value of 61% and a negative predictive value 
of 94.5% (Table 4). 
Among the 575 patients evaluable for tolerance, 
540 samples were received by the central laboratory and 
385 were taken into account in the results because they 
were received within 3 days of sampling. According to 
the criteria described in the Patients and Methods 
Table 4 Sensitivity of the GABHS rapid diagnostic test: 
results compared with those of culture in patients with an 
initial sample received within 3 days at the central 
laboratory 
Culture 
Negative Positive Total 
Rapid test not done 0 2 - 
Negative rapid test 29 1 17 308 
Positive rapid test 29 46 75 
Total 320 63 383 
Sensitivity: 46/63=73.02%. 
Specificity: 291 /320=90.94%. 
Positive predictive value: 46/75=61.33%. 
Negative predictive value: 291 /308=94.48% 
Table 5 Pathogens cultured at inclusion (385 throat swabs) 
Pathogen tI (Yo) 
section, strains were considered significant (i.e. probably 
pathogenic or copathogenic) in 185 (48%) samples, 
23% of which yielded more than one potential patho- 
gen. The nature and frequency of the isolates are given 
in Table 5 .  
Eradication of group A streptococci 
Among the 59 patients evaluable for this parameter, 
bacteriologic efficacy was satisfactory (eradication of 
group A streptococci) in 96% (22/23) cases on CPD, 
100% (16/16) on PNV and 95% (19/20) on AMC 
(statistically not significant). The two bacteriologic 
failures (one patient on CPD and one on AMC) were 
clinical successes at the end-of-treatment assessment. 
Tolerance 
Among the 575 patients evaluable for tolerance, 64 
experienced at least one side effect. The number of 
patients who experienced at least one side effect was 
lower in the CPD group (2/188 patients: 1%) than in 
the PNV group (16/187 patients: 8.6%) or the AMC 
group (46/200 patients: 23%). These differences were 
significant (p<O.OOl  for CPD versus AMC, and CPD 
versus PNV). Side effects were mainly of a gastro- 
intestinal nature, and occurred in two patients on CPD, 
nine patients on PNV and 42 patients on AMC. Side 
effects necessitated treatment withdrawal in 13 cases 
(seven patients in the PNV group, six in the AMC 
group, and none in the CPD group). 
Compliance 
Among the 566 cases in which the number of tablets 
effectively taken was noted, 17 (9%) of the 183 patients 
on PNV and 16 (8%) ofthe 196 patients on AMC were 
considered as showing poor compliance (less than 80% 
of the planned tablets). In contrast, this occurred in 
none of the 187 patients on CPD. The difference 
between the CPD group and the other two groups was 
significant (p<O.OOl for both comparisons). 
GABHS 65 (16.9) 
GCBHS 23 (6) 
GGBHS 8 (2.1) 
Haernophilus injuenzae" 5 (1.3) 
Staphylococcus uureusa 22 (5.7) 
Enterobacteriaceaeh 51 (13.2) 
Non-fermenting Gram-negative bacilli 13 (3.4) 
GABHS=group A P-hemolytic streptococci; GCBHS=group C 
P-hemolytic streptococci; GGBHS = group G P-hemolytic 
streptococci. 
samples without P-hemolytic streptococci, including one sample 
that contained both Huemophilns injuenzue and Staphylococcus (weus.  
the samples in which none of the above species were isolated, 
including a sample containing both a member of the Entero- 
bacteriaceae and non-fermenting Gram-negative rods. 
DISCUSSION 
The optimal treatment of acute pharyngitis is a matter 
of debate in several countries. The main preoccupation 
is to eradicate group A streptococci, in order to prevent 
acute rheumatic fever. Other considerations are cost 
and the impact of antibiotics on the microbial ecology. 
In France, GABHS rapid screening tests are not avail- 
able for reasons inherent in the public healthcare 
system. The recommendation is thus to treat all acute 
episodes of pharyngitis with antibiotics, regardless of 
the age of the patient, a 10-day course of PNV remain- 
ing the reference treatment. For French authorities, 
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p-lactam agents combined with P-lactainase inhibitors, 
and p-lactamase-resistant cephalosporins should be 
reserved for recurrent pharyngitis. O n  the other hand, 
a number of shorter treatment courses have been pro- 
posed; however, they have been exclusively assessed in 
patients with acute streptococcal pharyngitis [15-19, 
This is the first trial of a 5-day treatment with CPD 
at a dose of 100 nig morning and evening for recurrent 
pharyngitis irrespective of bacterial etiology. In order to 
conduct a study with nationwide relevance, and to 
assess the value of the routine use of thr GABHS rapid 
test, we chose to select as investigators a large number 
of general practitioners scattered throughout the French 
territory, who were asked to recruit three patients each. 
A 73% sensitivity of the GABHS rapid test was denion- 
strated in this setting. This study had an open design, 
so that a cost-effectiveness study could be conducted in 
parallel, and the compliance to regimens with different 
daily doses and different durations could be assessed. To 
minimize judgment biases, all the files were blindly 
reviewed by the study coordinator. 
Our results, obtained in a large population, show 
that 5 days of treatment with CPD is as effective, in 
clinical terms, as a 10-day course of AMC or PNV 
in the treatment of the initial acute symptoms. In 
addition, the 5-day CPD schedule W.IS associated in 
this trial with a better compliance and a better clinical 
tolerance relative to the comparators. Although group 
A streptococci eradication rates were siniilar in the 
three treatment arms, definite conclusions about this 
secondary criterion cannot be drawn because of the 
small size of the population concerned. Unexpectedly, 
a significant fall in the rate of recurrent episodes 
occurring during the 6-month follow-up period was 
observed in the CPD group as compared to the PNV 
and AMC groups, with a high power of comparisons 
based on survival curves. 
Neither identification of viral agents nor bacterio- 
logic studies of the recurrent episodes were planned in 
our analysis. However, we were able ‘co establish that 
the bacteria isolated at the time of inclusion did not 
correlate with recurrence in any of the three treatment 
groups. It  should be noted that, besides treatment itself, 
additional factors interfering with the outcome are an 
age <40 and a frequency of episodes ofpharyngitis > 4  
per year. 
In these adult patients with a history of at least 
three clinical episodes of pharyngitis per year, the 
decrease in recurrence rate observed following a 5-day 
course of CPD is an interesting result which requires 
further confirmation and whose mechanism deserves 
further investigation. In addition, this 5-day treatment 
study reinforces the previous results iri trials of 5-day 
22-25]. 
courses of CPD in the treatment of streptococcal 
pharyngitis. 
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